Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Myelofibrosis
Closed
Phase 3
This trial is combining navitoclax with ruxolitinib for myelofibrosis.
It is open to people who:
have intermediate 2 or high risk myelofibrosis and
have not had a JAK2 inhibitor drug such as ruxolitinib
Recruitment start: 16 July 2021
Recruitment end: 24 October 2022
Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.
Dr Donald McLornan
AbbVie
Last reviewed: 25 Oct 2022
CRUK internal database number: 17482
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
